BACKGROUND Despite endorsement of digoxin in clinical practice guidelines, there exist limited data on its safety in
IDENTIFICATION OF THE STUDY COHORT. We identified patients with newly diagnosed, nonvalvular AF and seen within 90 days in an outpatient care setting. The requirement of a confirmatory AF diagnosis is intended to minimize the impact of rule-out diagnoses and improve specificity; this approach has been previously applied to Medicare (18, 19) and VA (12) The primary outcome was time to death, beginning from 90 days after index AF diagnosis. Death was ascertained using VA's validated Vital Status file, which has 97.6% agreement and 98.3% sensitivity for detection of deaths identified by the National Death Index (17) . We assumed that patients with no record of death were alive until September 30, 2011, the last date for which vital status records from all sources were fully ascertained.
CLINICAL COVARIATES. We determined baseline patient comorbidities by calculating a Charlson comorbidity score (20, 21) and by identifying comorbidity-specific ICD-9 codes up to 2 years before the index AF date, using algorithms based on the Agency for Healthcare Research and Quality's Clinical Classification System (22) . Internal checking of the data indicated no substantial increase in comorbidity ascertainment by extending the claims window for more than two years prior to the index date. The CHADS 2 score was calculated using diagnostic algorithms previously validated in VA data (23, 24) .
Receipt of concomitant outpatient drug therapies was ascertained using the same methods as for the primary exposure.
We estimated glomerular filtration rate (eGFR) using the Chronic Kidney Disease Epidemiology Collaboration formula (25) . We used the most recent This approach has been validated (27, 28) and used previously with VA data (29) . For all Cox models, the assumption of proportional hazards was found to be valid by examining Schoenfeld residuals.
PROPENSITY MATCHING. We also performed a separate Cox regression on patients matched by the propensity scores of digoxin receipt. Propensity scores were calculated, with receipt of digoxin as the dependent variable, by using multivariate logistic regression and baseline characteristics listed in Table 1 as independent variables. We tested pairwise interactions of covariates and retained the terms that significantly improved model fit. Propensity score balance and overlap were assessed using propensity score distributions and standardized differences in observed characteristics. Model fit was assessed using the Hosmer-Lemeshow goodness-of-fit test and the C-statistic. Patients receiving the study drug were matched 1:1 with nonrecipients using nearestneighbor matching without replacement. Finally, we used the Kaplan-Meier method to estimate cumulative incidence of death in both the full and propensitymatched cohorts, and log-rank tests to assess differences between treated and untreated groups.
STRATIFIED AND SUBGROUP ANALYSES. We tested for modification of the association between digoxin use and mortality using the chi-square test for a series of potential effect modifiers. A log-likelihood ratio test for nested models with n degrees of freedom,
where n ¼ the number of interaction terms, was used to assess model fit. Potential effect modifiers included age, sex, presence of HF, prior myocardial infarction (MI), and concomitant use of warfarin, beta-blockers, or amiodarone.
SENSITIVITY ANALYSES. We used the method of Lin et al. (30) to perform a 3-way sensitivity analysis to Table 1) . In patients receiving digoxin, the mean MPR was 0.79 AE 0.27, and 70% of digoxin users were on therapy 1 year after the index date.
Compared with nonrecipients, digoxin recipients were of similar age but had a higher prevalence of HF and receipt of beta-blockers, angiotensin receptor blockers, antiplatelet therapy, diuretic agents, and warfarin.
PROPENSITY-MATCHED COHORT. Online Figure 1 shows the propensity distribution and overlap for recipients and nonrecipients of digoxin in the full cohort. Researching the association of digoxin therapy with mortality in patients with newly diagnosed atrial fibrillation/atrial flutter (AF). CI ¼ confidence interval; HR ¼ hazard ratio; TREAT-AF ¼ The Retrospective Evaluation and Assessment of Therapies in AF.
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A U G U S T 1 9 , 2 0 1 4 : 6 6 0 -8 matched cohort) ( Table 2 ). Figure 2 shows the cumulative incidence of death in the propensity-matched cohort. Cumulative incidence of death was higher in the digoxin-treated patients versus the untreated group (p < 0.001).
RELATIONSHIP TO KIDNEY FUNCTION. With multivariate adjustment and propensity matching, digoxin was associated with a significant increase in risk of death among nearly all strata of eGFR, except dialysis patients ( Table 2 ). However, there was no evidence of effect modification present across strata of kidney function (p ¼ 0.76).
SUBGROUP ANALYSIS. Multivariate and propensitymatched analyses are shown for 9 clinically relevant subgroups in Table 3 . Overall, subgroup findings were SENSITIVITY TO UNMEASURED CONFOUNDING. We performed an analysis to determine whether an unmeasured confounder (or set of confounders) can explain the propensity-matched HR of digoxin for death (Fig. 3) . The curves compare the hypothetical prevalence of the unmeasured confounder(s) within the digoxin-treated group (x-axis) and within the untreated group (curves for 5%, 10%, 20%, 30%, and 40%), showing the hypothetical HR (y-axis) for allcause mortality that would need to be associated with this confounder. For example, if an unmeasured confounder was present in 30% of untreated patients (Fig. 3 , orange line) and in 50%, 60%, or 80% of digoxin-treated patients (x-axis), then the HR required for the confounder to account for the observed difference (i.e., to shift the upper 95% HR confidence interval to 1.00) would be 2.5, 1.9, and 1.7, respectively.
As an example of an unmeasured confounder, suppose that patients treated with digoxin had greater frailty and that this was not captured with the current variables. If frailty was present in 5% of untreated patients (Fig. 3, red Cumulative Incidence, % (34) . Therefore, we believe that unmeasured confounding of sufficient severity to explain our findings is not likely.
STUDY LIMITATIONS. Our study is nonrandomized. The analysis cohort predominantly consists of male veterans, which limits generalizability of findings to women, although we did examine the mortality association with digoxin among women in subgroup analysis. We were unable to evaluate treatment dose on the basis of available data, although the mortality association was consistent across all strata of renal function and after adjustment for medication adherence.
Because AF is a progressive disease, the choice to include patients with new (incident) AF would be expected to minimize survival bias on the basis of duration of AF, but could also limit generalizability of our findings in prevalent AF cohorts. Additionally, survival bias could still occur if patients received the exposure or confounding therapies for other conditions before the index AF date.
We also could not measure HF severity, on the basis of symptom class, ejection fraction, or HF hospitalizations. Differences in HF severity could be a source of unidentified confounding, which we attempted to address through our sensitivity analysis.
Although we specified adherence to digoxin as a timevarying covariate, there is a possibility that timevarying confounders, such as discontinuation of other cardiovascular medications, could influence survival.
We used all-cause mortality rather than causespecific mortality, which could prevent a more meaningful determination of how drug exposure may have led to death. However, in 1 AFFIRM substudy, the magnitude of the HRs for digoxin was similar for all-cause, cardiovascular, and arrhythmic death (9) . A U G U S T 1 9 , 2 0 1 4 : 6 6 0 -8

